Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 03, 2015 7:43 AM ET

Biotechnology

Company Overview of Agios Pharmaceuticals, Inc.

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK...

38 Sidney Street

2nd Floor

Cambridge, MA 02139

United States

Founded in 2007

128 Employees

Phone:

617-649-8600

Key Executives for Agios Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 57
Total Annual Compensation: $425.0K
Principal Financial Officer, Principal Accounting Officer and Senior Vice President of Finance
Age: 43
Total Annual Compensation: $269.1K
Chief Operating Officer
Age: 59
Total Annual Compensation: $350.0K
Chief Scientific Officer
Age: 58
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

Agios Pharmaceuticals, Inc. Key Developments

Agios Pharmaceuticals Inc. Announces Collaboration with Celgene Corp. to Initiate Clinical Development of AG-881 in the Second Quarter of 2015

Agios Pharmaceuticals Inc. in collaboration with its cancer metabolism partner Celgene Corp. plans to initiate clinical development of AG-881 in the second quarter of 2015. AG-881 will be the third IDH, or isocitrate dehydrogenase, mutant inhibitor discovered by Agios to enter clinical development. Under the terms of the new AG-881 collaboration, Agios will receive an initial payment of $10 million from Celgene in the second quarter of 2015 and is eligible to receive regulatory milestone payments of up to $70 million.

United States Food and Drug Administration Grants Agios Pharmaceuticals, Inc.'s Orphan Drug Designation for its Investigational Medicine AG-348

Agios Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designation for its investigational medicine AG-348 for the treatment of pyruvate kinase (PK) deficiency, a rare form of hemolytic anemia. AG-348, a first-in-class, orally available activator of pyruvate kinase-R (PKR) enzymes, met its primary endpoints in two Phase 1 healthy volunteer studies 'a single ascending dose study and multiple ascending dose study. In addition, data presented in December 2014 at the 54th Annual Meeting of the American Society of Hematology (ASH) provided early proof-of-mechanism for AG-348. Based on these findings, Agios plans to initiate a Phase 2 clinical trial in patients with PK deficiency in the first half of 2015. Based on findings presented at ASH, Agios expects to initiate a Phase 2 study of AG-348 in patients with PK deficiency in the first half of 2015. The company plans to provide final results from the Phase 1 multiple ascending dose study at a medical conference in mid-2015. A natural history study of PK deficiency is also ongoing and Agios expects to report initial data from this study at a medical conference in mid-2015.

Kevin Starr, a Board of Director of Agios Pharmaceuticals, Inc. Not to Stand for Re-Election at its 2015 Annual Meeting of Stockholders

On March 10, 2015, Kevin Starr notified Agios Pharmaceuticals, Inc. of his decision not to stand for re-election to the Board of Directors at the company when his current term expires at the company's 2015 annual meeting of stockholders. Mr. Starr will continue to serve as the chairman of the Board, a member of the Audit Committee, and the chair of the Nominating and Corporate Governance Committee until the conclusion of the 2015 annual meeting of stockholders.

Similar Private Companies By Industry

Company Name Region
Ekips Technologies United States
Rodin Therapeutics Inc. United States
GenoMed, Inc. United States
SARCO Inc. United States
Animal Cell Therapies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Agios Pharmaceuticals, Inc., please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.